Is My Paper Ready for Brain? The Clinical-Neurology Readiness Test

These are the hard constraints that gate readiness. Confirm each against the live OUP page; the right-hand source column shows where each comes from.

A note on the timeline number: the live Oxford page advertises a fast median (a few days) to first decision, but that figure is dominated by quick desk rejections. The ~35-day SciRev figure is the more honest read for a manuscript that clears the desk. Readiness is not about speed; it is about surviving the read.

Brain runs an Editorial Board read at submission. Every paper is seen by one or more Board members before it reaches external review, and the desk decision arrives quickly when a manuscript fails the journal's core mandate. These are the patterns that get papers returned before peer review:

The single-tier paper. Brain wants mechanism AND clinical-neurology consequence in the same manuscript. Purely basic neuroscience in healthy subjects without a disease bridge, or a descriptive clinical study without mechanistic depth, both fail the test. The editor's filter is concrete: does this change how a neurologist evaluates, diagnoses, or treats patients?

Visible scientific flaws at first read. A sample size inadequate for the claim, missing controls, or statistical methods that do not fit the design are all desk-rejection triggers. Reviewers do not get a chance to debate a paper whose evidence is structurally insufficient on the first pass.

Scope mismatch. Pure psychiatry, pure basic neuroscience, and pure neuroimaging methodology are routinely redirected. The journal is clinical neurology with translational depth, and a paper that does not sit in that lane wastes a cycle.

Cover letter that pitches novelty without consequence. "First to show X in disease Y" is not a clinical implication. Editors look for the sentence that says what the finding changes for patients or for disease understanding.

Format misuse. A case series written up as an Original Article when it should be a Short Report or Letter signals that the author has not calibrated the contribution to the journal's article types.

Run a Brain submission readiness check to surface which of these your manuscript trips before the Editorial Board does.

Cohort and sample size. State the sample size and justify it against the primary outcome. For clinical cohorts, report inclusion and exclusion criteria and any attrition. An underpowered study is the most common quantitative reason a sound idea gets returned; the readiness fix is a power calculation or an honest reframing of the claim to what the data support.

Statistical analysis. Report the full picture: the test, why it fits the design, effect sizes, and confidence intervals, not just p-values. Pre-specify the primary outcome. Reviewers at Brain read the supplement specifically to check whether analytical decisions were quietly moved out of the main text. If your statistics only survive in the supplement, they are not ready.

Controls. Controls must be appropriate to the design and present in the main figures. For mechanistic work, that means the causal experiment, not only the correlational observation. A mechanism claimed without a loss-of-function, gain-of-function, or equivalent causal test reads as overreach.

Figures. Original Articles allow up to 8 figures or tables combined. The first one or two figures should carry the central claim. The readiness test: if you deleted every supplementary figure, would the main mechanistic argument still stand? If not, restructure before you submit.

Methods. The design must be reproducible from the main text alone. Reviewers should not need the supplement to understand what was done. Match the reporting checklist to the study type (STROBE for observational, CONSORT for randomized trials, PRISMA for systematic reviews).

Clinical-significance framing. This is the readiness gate that fails the most otherwise-strong papers. The abstract and cover letter must state the neurological consequence in plain terms. Write the sentence a neurologist would underline: what does this change for diagnosis, treatment, or disease understanding?

Abstract. A 300-word structured abstract has to do double duty: state the mechanism and the consequence. If the abstract hints at importance but cannot name the actual advance simply, the editor's read is already losing momentum.

In our pre-submission review work with Brain submissions, a clear set of named patterns separates the manuscripts that clear the Editorial Board read from the ones that come back within days. These are the recurring failure modes we flag before authors commit a submission cycle, and they are testable against your own draft.

The implied-consequence paper. Across our Brain pre-submission reviews, the most consistent miss is mechanistic neuroscience where the disease or clinical consequence is hoped-for rather than shown. The manuscript spends its figures on an elegant pathway and defers the neurological payoff to a single discussion sentence. The fix is structural, not cosmetic: the clinical-neurology consequence has to be demonstrated and stated in the abstract.

We test it by reading only the abstract and asking whether a neurologist could name what changes for patients. If they cannot, the paper reads as excellent neuroscience rather than flagship neurology, and Brain's editors make that distinction fast.

The supplement-dependent mechanism. A recurring pattern in Brain-targeted manuscripts is that the strongest mechanistic evidence sits in the supplementary figures while the main figures carry weaker, more descriptive results. Brain has a generous 5,000-word limit relative to many neurology journals, which paradoxically tempts authors to push the load-bearing controls and the causal experiment out of the main text.

We apply a concrete test: delete the supplement and check whether the central mechanistic claim still stands on the main figures alone. When it does not, the manuscript is not ready, because Brain reviewers read the supplement looking for exactly the omitted controls and analytical decisions that were relocated there.

The underpowered or post-hoc statistics package. In manuscripts coming through pre-submission review for Brain, a frequent quantitative failure is a cohort that is underpowered for the claimed effect, or a results section where the only significant findings are post-hoc rather than tied to a pre-specified primary outcome. We flag missing sample-size justification, effect sizes reported without confidence intervals, and statistical tests that do not match the design.

These are the visible-at-first-read flaws that get a paper desk-rejected before external review, so closing them is higher-leverage than any amount of prose tightening.

The scope-drift submission. Across our Brain pre-submission reviews, a portion of manuscripts are strong in their own lane but outside Brain's clinical-neurology mandate: pure psychiatry, pure basic neuroscience in healthy subjects, or neuroimaging methodology with no disease application. We surface this early because the editorial filter is unforgiving, and the better move is often a confident submission to Neuron, Journal of Neuroscience, or Lancet Psychiatry rather than a hopeful one to Brain. Recognizing scope drift before submission saves a full cycle.

The novelty-without-consequence cover letter. A pattern we see repeatedly in Brain submission packages is a cover letter that leads with "first to show" but never names the clinical implication. Brain editors are reading for consequence, not priority. We rewrite the framing so the cover letter and abstract make the same mechanistic-and-clinical promise, and we check that the first figure supports that promise immediately rather than several pages in.

A Brain manuscript scope and readiness check runs these tests across the abstract, methods, statistics, figures, and cover letter in one pass before you submit.

If the readiness matrix points away from Brain, route deliberately rather than submitting on hope.

The Brain Communications transfer route is the highest-yield fallback for a desk-rejected Brain paper whose clinical-neurology work is sound. It keeps the same editorial team and avoids a cold start at a new journal.